

Personalised Cancer Medicine Flashcards 2021

Melanoma



Standard¹

BRAF

Recommended²

KIT*

*in mucosal or acral melanoma or melanoma associated with sunlight

Currently
not recommended

NRAS
GNAQ/GNA11
PTEN
MITF
CDKN2A
MHC-II

Tumor mutational burden

The **Standard** category is based on current treatment indications with approved funding by the Spanish National Health System
The **Recommended** category is based on current recommendations by EMEA and FDA

1. Martín-Algarra S, Fernández-Figueras MT, López-Martín JA, et al; Spanish Society of Pathology; Spanish Society of Medical Oncology. Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2014 Apr;16(4):362-73. doi: 10.1007/s12094-013-1090-5.
2. Scherrer E, Rau R, Lorenzi M, Shui I, Townson S, Larkin J. Systematic literature review for the association of biomarkers with efficacy of anti-PD-1 inhibitors in advanced melanoma. Future Oncol. 2021 Mar 30. doi: 10.2217/fon-2021-0154.
3. Mao L, Dai J, Cao Y, et al. Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway. Eur J Cancer. 2021 Mar 23;148:297-306. doi: 10.1016/j.ejca.2021.02.021.



Cátedra de
Medicina Personalizada de Precisión

UAM Universidad Autónoma
de Madrid

